The surge in poison control calls linked to semaglutide (Ozempic and Wegovy) post-2021 FDA approval for weight management has sparked concern. Researchers from the University of Texas attribute this spike to accidental dosing errors, not intentional misuse. This highlights the importance of patient education on proper weekly dosing and gradual dose increases. The study reveals a common mistake: patients taking the medication daily instead of weekly and starting with the highest dose immediately, rather than following the recommended step-by-step schedule. This underscores the need for clear, accessible information to prevent avoidable incidents and ensure patient safety.
